cyrilzakka/clinical-trials huggingface dataset:
Effect of Shock Wave Therapy on Upper Trapezius Trigger Points in Patients With Cervicogenic Headache.

Control group will receive US, TENS, IR and exercises. The treatment group will receive the same program in addition to shock waves therapy. Patients will receive 3 sessions per week for 4 weeks.

Control group will receive US, TENS, IR and exercises. The treatment group will receive the same program in addition to shock waves therapy. Patients will receive 3 sessions per week for 4 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Fifty patients from both genders.
* Age ranging from 20 to 40 years.
* Referred by an orthopedist with a diagnosis of Mechanical neck dysfunction (MND) to physical therapy at the outpatient clinic of the Faculty of Physical Therapy, MTI University.

Exclusion Criteria:

* All other disorders.
Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172

RATIONALE: Gathering information about patients with ovarian cancer over time may help doctors learn more about a patient's use of medical services and the cost of these services.

PURPOSE: This clinical trial is collecting information about the patient's health and use of medical resources over time in patients with stage III ovarian cancer receiving paclitaxel and cisplatin on clinical trial GOG-172.

OBJECTIVES:

* Determine the feasibility of collecting data on medical resource utilization and costs incurred in the care of patients with stage III ovarian cancer treated with intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) paclitaxel, and IP cisplatin on a randomized, controlled clinical trial.
* Determine the feasibility of collecting data on resource utilization incurred outside GOG institutions through the use of patient diaries.
* Assess the work load required to collect this data, in terms of mean number of hours required to complete medical resource utilization forms.

OUTLINE: Data on medical resource units consumed (including length of hospital stay, length of time using operating room, units of drugs and blood products administered, number of diagnostic tests received, and number of physician visits needed) are collected on all patients.

Quality of life is assessed prior to randomization on clinical trial GOG-172, prior to the fourth course of chemotherapy, after the sixth course of chemotherapy, and at 3 months and 6 months after the sixth course of chemotherapy. Patients complete diaries throughout treatment with chemotherapy and for 12 months after treatment.

Data collected are used for analysis of economic impact, quality of life, neurotoxicity, and sociologic characteristics associated with these treatment regimens.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 1 year.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of stage III ovarian cancer
* Concurrent enrollment on clinical trial GOG-172 required

PATIENT CHARACTERISTICS:

Age:

* Not specified

Performance status:

* GOG 0-3

Life expectancy:

* Not specified

Other:

* Able to communicate in English or Spanish

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* Not specified

Radiotherapy

* Not specified

Surgery

* Not specified
Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects

The purpose of this single center, prospective case series is to evaluate the effective management of split-thickness skin graft donor site wounds using Opticell Ag (Chitosan-based dressing).


Eligibility Criteria:
Inclusion Criteria:

* Inpatient status at study site
* Subject must be receiving a split-thickness skin graft (STSG)
* Wounds must not exceed 10% total body surface area (TBSA)
* Any donor site
* Ability to comply with necessary wound care/follow up

Exclusion Criteria:

* Subject is pregnant
* Subject has been diagnosed with Diabetes
* Subject is a smoker
* Subject takes steroids
* Subject is sensitive and/or allergic to shellfish and/or silver
* Wounds that exceed 10% total body surface area (TBSA)
* Inability to comply with necessary wound care/follow up
Self-Efficacy Levels of Nurses on Safe Blood and Blood Product Transfusion

A quasi-experimental study was conducted in a pre-test-post-test design to investigate the self-efficacy levels of nurses working in a cardiovascular surgery Intensive Care Unit regarding safe blood and blood product transfusion and the effects of online training.

Blood transfusion is a life-saving and therapeutic procedure, but it also carries high risks. Nurses have the greatest responsibility in preventing complications related to blood transfusion. To maintain safe practice standards, healthcare institutions need to use national transfusion guidelines and establish blood banks/transfusion laboratories, transfusion protocols, and hemovigilance teams. From the moment the blood is collected from the donor to the end of the transfusion, administering the right blood to the right patient, storing the blood appropriately, monitoring the patient for signs of reactions during the procedure, and having sufficient knowledge and skills on precautions to be taken when complications develop are the responsibilities of nurses regarding transfusion. For nurses to fulfill their duties in this regard, they must have up-to-date knowledge, skills, and competence. Since CVS intensive care clinics are where blood transfusion is performed most frequently, it is of particular importance that the nurses working in these units have sufficient knowledge on the subject and are strengthened in this regard. Based on this situation, the research is planned to determine the self-sufficiency levels of nurses working in the CVS intensive care unit regarding blood transfusion and to contribute to the field by eliminating deficiencies in this regard through training.

Eligibility Criteria:
Inclusion Criteria:

* volunteer nurses

Exclusion Criteria:

* Nurses who did not want to participate in the study
Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

The purpose of this study is to determine whether Warfarin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients with Hypersplenism after Laparoscopic Splenectomy.

After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will be recorded and the patient will be randomized into either interventional (warfarin) or control (aspirin) group. From postoperative day 3, patients in interventional (warfarin) group will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year, patients in control (aspirin) group will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year, and both groups will be along with five days of subcutaneous injection of Low Molecular Weight Heparin and three months of oral Dipyridamole. Every 3 months the Doppler screening for the occurrence of portal vein thrombus (PVT) or spleno-mesenteric thrombosis will be done for all patients. Both groups will receive the therapy for one year irrespective of the Doppler findings in relation to portal vein thrombus occurrence. Then one year monitoring will be done in the both groups as per the primary or secondary outcome.

Eligibility Criteria:
Inclusion Criteria:

* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
* Splenomegaly with secondary hypersplenism, Platelet count \< 50\*10\^9/L
* No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and angio-CT
* Informed consent to participate in the study

Exclusion Criteria:

* Hepatocellular carcinoma or any other malignancy
* Hypercoagulable state other than the liver disease related
* DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs
* Base line INR \>2
* Child-Pugh grade C
* Recent peptic ulcer disease
* History of Hemorrhagic stroke
* Pregnancy
* Uncontrolled Hypertension
* Age\>75 yrs
* F2 varices with red whale marks or F3 varices
* Bleeding portal hypertension
* Human immunodeficiency virus (HIV) infection
PEMF and PEC Blocks in Mastectomy Reconstruction Patients

This is a prospective randomized controlled double-blind interventional study comparing the effect of pulsed-electromagnetic field device (PEMF), pectoral interfascial block (PIB), and placebo on postoperative pain control. This study has the interdisciplinary cooperation of the regional anesthesia group, and the breast and plastic surgery divisions. All female patients with breast cancer evaluated at Columbia University Medical Center (CUMC) who are undergoing unilateral or bilateral mastectomy with tissue expander reconstruction will be offered enrollment in this prospective study.

Chronic pain after mastectomy, or breast tissue removal, is very common with almost half of women experiencing some type of residual pain and even 13% characterizing it as severe. Poor acute postoperative pain control is not only associated with development of chronic pain, but has also been shown to be associated with delayed wound healing. Therefore, optimization of postoperative pain control is paramount not just for patient comfort, but to decrease immediate and long-term postoperative complications.

There are two adjunctive modes of perioperative pain control currently in use at Columbia University Medical Center (CUMC). The first mode uses pulsed electromagnetic fields (PEMF) and consists of a noninvasive device placed over dressings around the surgical site. The second is a regional anesthetic and -the pectoral interfascial block (PIB) in which a long-lasting local anesthetic (bupivacaine/ropivacaine) is injected into the surgical dissection area. Both of these techniques for postoperative analgesia have been shown to be effective in different types of breast surgery, but there is no current literature comparing the two modalities in their efficacy in reducing postoperative pain. There is also no current literature in their efficacy in the mastectomy and tissue expander patient population. The proposed trial is a prospective, randomized, controlled, double-blind trial to evaluate the efficacy of these two modalities of postoperative analgesia in patients undergoing mastectomy and tissue expander reconstruction.

Eligibility Criteria:
Inclusion Criteria:

* Subjects must be female
* Subjects must be 18 years or older
* Subjects must be undergoing unilateral or bilateral mastectomy with tissue expander reconstruction

Exclusion Criteria:

* Allergy to all narcotic medications
* Intake of any chronic opioids or pain medications preoperatively for a chronic condition or chronic use.
Postoperative Pain Control With Lipossomic Extended Release Bupivacaine

Randomized trial of intraoperative intercostal block with bupivacaine with epinephrine compared to lipossomal extended release bupivacaine.

Patients undergoing minimally invasive thoracic surgery will be randomized to receive 0.05% bupivacaine with 1:200,000 epinephrine (control group) or extended release lipossomal bupivacaine. Primary outcomes are postoperative pain measured by visual analog scale, amount of morphine equivalent narcotics used, and postoperative complications. Patients are excluded if they undergo open thoracotomy, or minimally invasive decortication.

Eligibility Criteria:
Inclusion Criteria: Patients who will be undergoing minimally invasive thoracic surgery

* Patients who will be undergoing minimally invasive thoracic surgery

Exclusion Criteria:

* Open surgery
* Chronic use of narcotics
* Use of pregabalin or similar
* Significant liver or kidney dysfunction
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Angioid Streaks
* Choroidal neovascularization associated
* Untreated patients or patients treated once with PDT

Exclusion Criteria:

* Ocular surgery excepting uncomplicated phacoemulsification
* Glaucoma or any other ocular pathology
Effect of Moderate Weight Loss in Metabolically Abnormal Lean Subjects

Obesity is associated with a constellation of cardiometabolic abnormalities (including insulin resistance, elevated blood pressure and dyslipidemia) that are risk factors for diabetes and cardiovascular disease. Weight loss can improve all of the cardiometabolic abnormalities associated with obesity. Up to \~25% of lean people (Body Mass Index \[BMI\] 18.5-24.9 kg/m²) have many of the cardiometabolic abnormalities associated with obesity and are referred to as metabolically abnormal lean (MAL) people. However, the MAL phenotype is not well characterized, and it is unclear whether weight loss has beneficial metabolic effects in already lean people. Accordingly, the goal of this study is to: 1) carefully phenotype MAL people and 2) evaluate the effect of moderate (8-10%) diet-induced weight loss in MAL people. This will be investigated in 15 MAL (defined as having 2 or more of the following: intrahepatic triglyceride (IHTG) content ≥5.6%, glycated hemoglobin ≥5.7%, fasting plasma glucose concentration ≥100 mg/dl, 2-hr oral glucose tolerance test (OGTT) plasma glucose concentration ≥140 mg/dl, homeostatic model assessment of insulin resistance (HOMA-IR) ≥ 2.5) men and women. Only lean people who have a BMI ≥21.0 but \<25.0 kg/m² will be asked to lose weight to avoid the risk that participants become underweight (BMI \<18.5 kg/m²) during weight loss therapy.


Eligibility Criteria:
Inclusion Criteria:

* BMI 21.0-24.9 kg/m²
* Weight stable (+/- 2% for at least 3 months before enrollment)
* Two or more of the following: IHTG content ≥5.6%, HOMA- IR index ≥ 2.5, HbA1C ≥ 5.7%, 2-hr OGTT plasma glucose concentration ≥ 140 mg/dl, fasting plasma glucose concentration ≥ 100 mg/dl.

Exclusion Criteria:

* Women who are pregnant or breastfeeding
* Evidence of significant organ system dysfunction or disease (e.g., diabetes, chronic kidney disease, advanced heart disease, etc.)
* Men who consume \>21 units (e.g., glass of wine or bottle of beer) of alcohol per week and women who consume \>14 units of alcohol per week
* Use of dietary supplements or medications known to affect metabolism
* Eating disorder (assessed by using the Eating Disorder Examination Questionnaire \[EDE-Q\])
* Participation in structured endurance or resistance exercise program \>150 min/week
* Use of tobacco products
* Unable or unwilling to follow the study protocol or the research team believes that for any reason the volunteer is not an appropriate candidate for this study, including non-compliance with screening appointments or previous appointments/contact arrangements
* Individuals that take Coumadin or similar anticoagulants
* Use of antibiotics in last 60 days
* Previous bariatric surgery
* Cancer or cancer that has been in remission for \<5 years
* Major psychiatric illness
Investigate a Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects

Primary object: Evaluate Pharmacodynamic property and safety administered S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in healthy male subjects

Secondary object : Evaluate Dose-response of S-pantoprazole and pantoprazole and compare each dose-response


Eligibility Criteria:
Inclusion Criteria:

* Adult healthy males 20 to 45 years at screening
* BMI : 19kg/m2 \~ 26 kg/m2
* Blood Pressure : "140 mmHg ≥ sitting SBP ≥ 90 mmHg, 95 mmHg ≥ sitting DBP ≥ 50 mmHg"

Exclusion Criteria:

* Have history of significant hepatic, renal gastrointestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases
* Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer) or surgery (except for Appendectomy, hernia repair) affected the absorption of medications
* Have history of GERD, Gastric ulcer, Duodenal ulcer and H.pylori positive
* Hypersensitivity reactions to drugs of clinically significant hypersensitivity reactions in the history of benzimidazole (ex: pantoprazole, NSAID, antibiotic)
* Have a history of drug abuse
* unusual diet affected the absorption, distribution, metabolism, excretion of medications
* Subject who treated with any investigational drugs within 90 days before the administration of investigational drug
* Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates etc.) within 30days
* Previously donate whole blood within 60 days or component blood within 30 days or transfusion within 30 days
* Subject who have taken habitually caffeine (caffeine \> 5 units/day)
* Subject who have drunken habitually (alcohol \> 21 units/week, 1 unit = pure alcohol 10ml)or who are unable to quit drinking during this study or smoker
* Subjects deemed ineligible by investigator based on other reasons
Correlation of Serum Lactate and Activity of Multiple Sclerosis

Correlation of serum lactate and activity of multiple sclerosis and its correlation to different type of MS

Correlation of serum lactate and activity of multiple sclerosis and its correlation to different type of MS and magentic resonanace imaging , magentic resonanace spectroscopy

Eligibility Criteria:
Inclusion Criteria:

-Patients with multiple sclerosis (RRMS,PPMS and SPMS)

Exclusion Criteria:

-Patients with any other medical conditions that may affect the serum lactate level
Survivorship Care Plans in a Community Oncology Practice

This is a two part observational study evaluating the feasibility of implementing an EHR-based model within a community oncology practice.

Part 1: The research team will use a sociotechnical work systems model, developed by researchers at the University of Wisconsin (UW) Systems Engineering Initiative for Patience Safety (SEIPS), to guide analysis of the work system barriers and facilitators to implementing an EHR-based care planning model in community oncology practice, collected from direct observations.

Part 2: The research team will measure reach/maintenance (percentage of survivors with EHR-based survivorship care plans (SCPs) over a 9-month time period) and impact (pre/post survey of patient satisfaction and perceived care coordination).

Eligibility Criteria:
Inclusion Criteria:

* Clinicians: Provide cancer care to BrCa, CRCa or PrCa
* Clinicians: Are a physician, advanced practice practitioner, nurse, or equivalent
* Patients: Have a diagnosis of breast, colorectal, or prostate cancer for which and EHR-based SCP will be provided
* Patients: Have been treated with curative intent (e.g. surgery, chemotherapy and/or radiation therapy) for a Stage 1-3 cancer diagnosis
* Patients: Have received some part of active cancer treatment
* Patients: Have complete active treatment (defined as surgery, chemotherapy, and/or radiation therapy). HER2-based and endocrine therapies may be ongoing and do NOT need to have been completed

Exclusion Criteria:

* Unable to complete or unwilling to answer questions in English
* Patients: Received all active cancer treatment elsewhere (e.g. "observation - only" patients)
* Patients: Have metastatic cancer
Myofascial Induction Effects on Plantar Pressures and Stabilometry

The objective is to determine the effectiveness of myofascial Induction effects on plantar pressures and stabilometry variables. Forty healthy subjects (28 females and 12 males) will be recruited for a simple blind clinical trial. All subjects will be randomly distributed in two different groups: control group (sham treatment of myofascial Induction) and experimental group (myofascial Induction). Outcome measurements will be foot plantar pressure area (footprint) and center of pressure area (stabilometry) by the Balance Evaluation Systems test. Two trials will be recorded for each condition.


Eligibility Criteria:
Inclusion Criteria:

* Healthy individuals without pain.

Exclusion Criteria:

* Previous lower extremities surgery
* History of lower extremities injury with residual symptoms within the last year
* Evidence of a leg-length discrepancy of more than 1 cm
* Evidence of balance deficits
Tele-rehabilitation in the Home With Gaming as a Method of Improving Upper Extremity Function After Stroke

The purpose of the study is to determine whether a novel computer gaming hand exercise regimen would improve hand and arm function and be feasible in people with hemiplegia after Stroke affecting the hand.

A novel computer gaming hand exercise regimen has been designed for people with hemiplegia after Stroke affecting the hand. The design allows a broad range of common objects of daily life to be seamlessly transformed into 'therapeutic' input devices by instrumenting with a small motion sense mouse. Based on individual abilities and treatment needs, objects are selected to train specific fine/ gross dexterous functions. The object manipulations (therapeutic exercises) are then used to control and play any commercially available computer game, making practice challenging and engaging.

The study is of twelve weeks duration comparing the computer gaming and conventional hand exercises in ten people with hemiplegia after Stroke affecting the hand. The investigators hypothesize that the game based exercises will improve hand function and will be feasible. A mixed-effect repeated measures analysis of variance will be conducted to test pre to post treatment outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Time since stroke onset less than 1 year.
* Ability to actively extend at least 10 degrees at the Metacarpophalangeal and Interphalangeal joints and 10 degrees at the wrist. At least 30 degree of active flexion-extension at elbow and some active movements present at the shoulder joint.
* English speaking.
* No clinical evidence of cognitive impairment (screened by physician or therapist).
* Have a personal computer at home.
* Lives in Winnipeg.
* Able to provide informed consent.

Exclusion Criteria:

* Patients having excessive spasticity, pain or contractures in the more affected limb will not be included in the study.
* Convulsive seizures preventing adequate attention to task.
* Problem with vision.
* Aphasia.
* Apraxia.